Latest News News

Five IIDR Members Awarded More Than $14M in Federal Grants

CIHR winners

Top (left to right): Dr. Gerry Wright, Dr. Karen Mossman and Dr. Mark Loeb; Bottom (left to right): Dr. Zhou Xing and Dr. Mike Surette

Five research programs led by members of the Michael G. DeGroote Institute for Infectious Disease Research (IIDR) will receive more than $14M from the Canadian Institutes of Health Research (CIHR).

The grants, which will support cutting-edge research ranging from the discovery of novel antibiotics to the development of a global vaccination strategy to control Tuberculosis (TB), are part of a larger $667M investment from two of the federal agency’s funding competitions.

CIHR Foundation Grant awards

Established in 2015, the Foundation Grant competition provides long-term support of five to seven years for the pursuit of innovative, high-impact research programs.

  • Dr. Gerry Wright, professor in the department of Biochemistry and Biomedical Sciences and scientific director of the IIDR, will receive $4,246,166 to address the antibiotic resistance crisis. Wright’s work will focus on the mechanisms and origins of drug resistance and the discovery of new antibiotics and antimicrobial strategies.

CIHR Project Grant awards

The Project Grant competition provides short- and long-term support of one to five years to advance health-related knowledge, health research, health care, health systems, and/or health outcomes. 

  • Dr. Zhou Xing, professor in the department of Pathology and Molecular Medicine, will receive $875,355 to develop a new Tuberculosis (TB) vaccination strategy that will ultimately contribute to the effective control of lung TB around the world.
  • Dr. Karen Mossman, professor in the department of Pathology and Molecular Medicine, will receive $688,051 to discover and develop novel, generic antiviral therapies capable of protecting against new, emerging viruses.
  • Dr. Mike Surette, professor in the department of Medicine, will receive $653,649 to advance his studies of the human microbiome for the discovery of novel antibiotics, immunomodulators and probiotics.